1. Home
  2. HQI vs IPHA Comparison

HQI vs IPHA Comparison

Compare HQI & IPHA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo HireQuest Inc. (DE)

HQI

HireQuest Inc. (DE)

HOLD

Current Price

$17.03

Market Cap

232.1M

ML Signal

HOLD

Logo Innate Pharma S.A. ADS

IPHA

Innate Pharma S.A. ADS

HOLD

Current Price

$1.85

Market Cap

165.3M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
HQI
IPHA
Founded
2002
1999
Country
United States
France
Employees
75000
N/A
Industry
Professional Services
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
232.1M
165.3M
IPO Year
2008
2014

Fundamental Metrics

Financial Performance
Metric
HQI
IPHA
Price
$17.03
$1.85
Analyst Decision
Buy
Strong Buy
Analyst Count
1
4
Target Price
$13.00
$5.75
AVG Volume (30 Days)
13.0K
33.6K
Earning Date
05-08-2026
03-26-2026
Dividend Yield
2.08%
N/A
EPS Growth
73.08
N/A
EPS
0.31
N/A
Revenue
$30,640,000.00
N/A
Revenue This Year
N/A
$180.36
Revenue Next Year
$0.46
N/A
P/E Ratio
$56.16
N/A
Revenue Growth
N/A
N/A
52 Week Low
$7.38
$1.18
52 Week High
$19.01
$2.71

Technical Indicators

Market Signals
Indicator
HQI
IPHA
Relative Strength Index (RSI) 61.18 41.91
Support Level $12.14 $1.67
Resistance Level $17.78 $1.88
Average True Range (ATR) 0.71 0.11
MACD 0.01 -0.03
Stochastic Oscillator 86.92 15.89

Price Performance

Historical Comparison
HQI
IPHA

About HQI HireQuest Inc. (DE)

HireQuest Inc is a nationwide franchisor of offices providing direct-dispatch, executive search, and commercial staffing solutions in the light industrial and blue-collar segments of the staffing industry and traditional commercial staffing. The company's franchisees provide various types of temporary personnel through two business models operating under the trade names HireQuest Direct, HireQuest, Snelling, DriverQuest, HireQuest Health, Northbound Executive Search, and MRI. The company's primary source of revenue is royalty fees based on the operation of its franchised offices.

About IPHA Innate Pharma S.A. ADS

Innate Pharma SA is a clinical-stage biotechnology company. It is engaged in developing immunotherapies for cancer patients. The company's approach includes therapeutic modalities such as monoclonal antibodies, multispecific NK cell engagers through its ANKET platform, and antibody-drug conjugates (ADC). Its portfolio includes lacutamab, which is being studied for cutaneous T-cell lymphomas and peripheral T-cell lymphomas, and monalizumab, which is being developed in collaboration with AstraZeneca for non-small cell lung cancer. The company's revenue mainly consists of revenues from collaboration and licensing agreements and government financing for research expenditure in the form of research tax credits, as well as other grants.

Share on Social Networks: